MEDIFAST INC (MED) Stock News

MEDIROM MOTHER Labs announced it received an additional order from Japan Ground Self-Defense Force's 8th Division for its REMONY® remote health monitoring system, tripling the initial deployment scale. The system utilizes the MOTHER Bracelet®, a recharge-free smart tracker that monitors vital health metrics continuously without requiring charging, making it suitable for harsh training environments and heatstroke prevention.

HUTCHMED announced positive Phase II pivotal trial results for fanregratinib (HMPL-453) in treating advanced intrahepatic cholangiocarcinoma patients with FGFR2 fusion/rearrangement. The study achieved a 42.5% objective response rate, 6.9-month median duration of response, and 16.6-month median overall survival, with a manageable safety profile. The company received priority review status from China's NMPA for a New Drug Application in December 2025.

Dimensional Fund Advisors Ltd. disclosed a 1.41% stake in Advanced Medical Solutions Group PLC comprising 3,110,204 ordinary shares as of June 22, 2026. The disclosure includes a single purchase transaction of 112 shares at 22.3150 GBP per unit. Dimensional expressly disclaims beneficial ownership and notes it lacks discretion over 32,163 of the disclosed shares.

Preformed Line Products (NASDAQ: PLPC) announced a regular quarterly dividend of $0.21 per share, payable on July 20, 2026, to shareholders of record as of July 1, 2026. The dividend was declared by the company's Board of Directors on June 6, 2026.

GO Residential REIT completed acquisitions of 7 Dey Street in Tribeca and Ivy Tower in Times Square, increasing its portfolio to 2,545 residential suites (26% growth). The transactions are expected to be immediately accretive to AFFO per unit and were funded through available cash and $146.3 million in fixed-rate mortgage debt at 4.50%. The REIT approved a monthly cash distribution of $0.05325 per unit for June 2026.

Profusa has submitted a comprehensive response package to its European Notified Body GMED following successful completion of Stage 1 and Stage 2 assessments for CE Mark certification of its Lumee Oxygen Platform. The submission includes updates to technical documentation, quality system evidence, clinical evaluation activities, and validation information. The company remains committed to obtaining CE Mark certification to support European commercialization of its tissue oxygen monitoring technology.

HUTCHMED announced positive Phase III results for sovleplenib (HMPL-523) in treating warm antibody autoimmune hemolytic anemia (wAIHA). The drug demonstrated a 66% durable response rate versus 15% for placebo and showed rapid hemoglobin response with a favorable safety profile. China's NMPA accepted the New Drug Application for priority review in April 2026 and previously granted Breakthrough Therapy Designation in March 2026.

A class action lawsuit has been filed against Medpace Holdings, Inc. on behalf of shareholders for alleged securities fraud. The lawsuit was triggered after Medpace reported a book-to-bill ratio of 1.04 on February 9, 2026, significantly below company guidance, causing the stock to plunge 15.9% to $446.05 per share. The class period covers April 22, 2025 through February 9, 2026.

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary case involves Medpace Holdings, with a June 8, 2026 deadline for lead plaintiff claims. The lawsuit alleges Medpace made false statements about backlog cancellation rates and provided misleading growth projections. Additional class actions are mentioned for Veritone, Inc. and Babcock & Wilcox Enterprises, Inc.

Rosen Law Firm is notifying investors in Medpace Holdings, Upstart Holdings, and Babcock & Wilcox Enterprises of securities class action lawsuits. The firm alleges that Medpace made false statements about backlog cancellation rates and provided misleading growth projections. Investors with losses exceeding $100,000 are encouraged to secure counsel before the June 8, 2026 deadline to potentially serve as lead plaintiffs.

A class action securities fraud lawsuit has been filed against Medpace Holdings for allegedly making materially false statements about its business performance. The company missed its book-to-bill ratio guidance of 1.15, reporting only 1.04 due to record backlog cancellations, causing the stock to fall 15.9% on February 10, 2026. Investors who purchased shares between April 22, 2025 and February 9, 2026 can file a lead plaintiff motion by June 8, 2026.

IRADIMED CEO Roger E. Susi sold 7,500 shares indirectly through a trust for approximately $691,000 as part of a systematic Rule 10b5-1 plan. The sale represents routine liquidation rather than a negative signal, with the stock up 60.89% over the past year. The key investment variable is the adoption of the company's new infusion pump, with meaningful data expected by mid-2027.

Rosen Law Firm announces a securities class action lawsuit against Medpace Holdings, Inc. for allegedly making false statements about backlog cancellation rates and providing misleading growth projections. Investors who purchased MEDP stock between April 22, 2025 and February 9, 2026 may be eligible for compensation. The deadline to serve as lead plaintiff is June 8, 2026.

A securities class action lawsuit has been filed against Medpace Holdings, Inc. alleging that defendants made false and misleading statements regarding the company's backlog cancellation rates. The lawsuit claims defendants misrepresented cancellation rates as 'well behaved' and provided overly positive growth expectations that could not be sustained. Investors with losses exceeding $100,000 are encouraged to join the class action before the June 8, 2026 lead plaintiff deadline.

MEDIROM Healthcare Technologies reported Q1 2026 results showing strong Average Revenue Per Customer of 7,822 JPY (+7.7% YoY), significantly exceeding Japanese industry average. However, the company continues to face salon contraction with 287 locations (-21 YoY) and declining total customers (-13.9% YoY). The company is shifting to a hybrid staffing model with independent contractors now comprising 45.1% of therapists. World ID partnership generated ~31,000 verifications, while HealthTech division Lav® expanded to 106 health insurance providers with 13,226 cumulative users.

TOKYO, May 28, 2026 (GLOBE NEWSWIRE) -- This report presents an overview of our business performance and key performance indicators (KPIs) for the first quarter of 2026 (January–March 2026). It also highlights trends over the past five quarters (2025Q1–2026Q1) to provide investors with a broader perspective. Data includes salons with comparable financial and customer metrics. 1. Salon Operation Business In 2026Q1, our salon business recorded an Average Revenue Per Customer of 7,822 JPY (+7.7% YoY), exceeding the Japanese industry average of 4,806 JPY by approximately 3,016 JPY.(*1) This performance reflects the strength of our service offering, supported by our training infrastructure and an educational curriculum refined over 25 years. Over 120 diverse training courses (Technical skills, Hospitality, Knowledge, Management) Continuous training system even after therapist debut Strategy Update: Hybrid Staffing Model In addition, to support sustainable growth in our store operations and further enhance service quality, we have been strategically upgrading the working styles of our store staff (therapists) since 2025. In addition to traditional employment models centered on hourly wages and fixed salaries, we have been promoting the adoption and expansion of a professional contractor (independent contractor) model. Key Performance Indicators (KPIs) Metric 2025Q1 2025Q2 2025Q3 2025Q4 2026Q1 YoY Change Number of Salons (*2) 308 304 299 292 287 -21 Salons Total Customers (*3) 223k 234k 232k 208k 192k -13.9% Revenue Per Customer (*4) 7,263 7,259 7,560 7,830 7,822 +7.7% Repeat Ratio (*5) 77.1% 77.1% 76.8% 78.3% 78.0% +0.9pt Operating Ratio (*6) Full story available on Benzinga.com

Medx Holdings (MEDH), rebranding to Dazed Inc., has submitted a DEA registration application through its subsidiary Lazydaze ABQ LLC to operate federally registered medical cannabis operations following the rescheduling of medical marijuana to Schedule III. The company reported Q1 2026 revenue growth of 52% and profit growth of 70%, with plans for multi-city expansion and product rollouts.

Rosen Law Firm is soliciting investors who suffered losses in Medpace Holdings, Stellantis N.V., and Blaize Holdings to join securities class action lawsuits. The Medpace case alleges the company made false statements about backlog cancellation rates and provided misleading growth projections. The lead plaintiff deadline for Medpace is June 8, 2026.

Austin, Texas , May 26, 2026 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE MEDX HOLDINGS (MEDH) REPORTS EXCEPTIONAL Q1 2026 FINANCIALS: REVENUE SURGES, EXPANSION ON TRACK, AND CEO TO SPEAK AT HEMP BEVERAGE EXPO AUSTIN, Texas — May 26, 2026 — MedX Holdings, Inc. (OTC: MEDH ) (soon to be Dazed Inc., pending ticker symbol DAZE), a dynamic brands and acquisition company focused on the emerging hemp, cannabis, and hospitality industries, today announced its financial results for the first quarter ended March 31, 2026. The company is thrilled to report significant year-over-year revenue and gross profit growth, continued profitability, and major traction in its nationwide franchise expansion. Q1 2026 Financial Highlights: Accelerated Growth and Profitability The first quarter of 2026 reflects the power of MedX's strategic focus on high-margin branding, efficient operations, and calculated expansion. Key financial milestones from the Q1 2026 consolidated financial statements include: Solid Revenue Growth: Q1 2026 revenues reached $521,874, representing an impressive 52.7% increase compared to revenues of $341,711 in Q1 2025. Surging Gross Profit: Gross profit for the quarter climbed to $398,990, a 70.6% jump from the $233,793 reported in the same period last year. Sustained Profitability: The company maintained a positive bottom line, reporting a net income of $22,203 for the three months ended March 31, 2026. Expansion on Track: Bringing the "Third Place" to New Cities Following the momentum built in late 2025, ... Full story available on Benzinga.com

MedX Holdings announced Q1 2026 results with continued net profitability and debt reduction. The company is rebranding to Dazed Inc. (ticker: DAZE) and expanding with three new LazyDaze + Coffeeshop locations in San Marcos, Houston, and Baltimore. The company is also finalizing partnerships for Lazydaze Coffee and K-Cup products and capitalizing on cannabis's federal reclassification to Schedule III.

Five Iron Golf opened its first Texas location in Fort Worth's Near Southside district, celebrating with tournament-week specials tied to the Charles Schwab Challenge at Colonial Country Club. The 10,000-square-foot venue features 12 Trackman simulators, a full-service bar, and entertainment amenities. Special offers include complimentary simulator time for anyone named Charles and appetizers for tournament attendees.

Austin, Texas, May 22, 2026 (GLOBE NEWSWIRE) -- MEDX HOLDINGS ANNOUNCES Q1 2026 HIGHLIGHTS, MULTI-CITY EXPANSION, AND CORPORATE ACTION TO REBRAND AS DAZED INC. (TICKER: DAZE) AUSTIN, Texas — May 22, 2026 — MedX Holdings, Inc. (OTC: MEDH ), a leader in the converging cannabis, hemp, and hospitality sectors, today announced its operational and financial highlights for the first quarter of 2026. Building on the net profitability achieved in Q4 2025, the company continues to execute its aggressive expansion strategy, marked by upcoming store openings, strategic product partnerships, and a major corporate rebranding initiative to align with its rapidly growing consumer footprint. Corporate Action: Rebranding to Dazed Inc. To align the company's corporate identity with its flagship consumer brands and long-term vision, MedX Holdings has announced its intention and initiated the required corporate actions to change its name to Dazed Inc. Alongside this name change, the company intends to request a formal ticker symbol change to DAZE . This strategic evolution reflects the company's dominant focus on scaling the Lazydaze franchise ecosystem and Dazed Distribution networks. Q1 Financial and Operational Milestone Highlights Continued Debt Reduction: MedX sustained its disciplined focus on balance sheet strength, further paring down long-term liabilities throughout Q1 to enhance cash flow and shareholder equity. Lazydaze Coffee & K-Cup Partnerships: The company is currently in the final stages of talks with potential strategic partners to massively scale ... Full story available on Benzinga.com

Rosen Law Firm is reminding investors who purchased Medpace Holdings common stock between April 22, 2025 and February 9, 2026 of the June 8, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Medpace made false and misleading statements regarding its backlog cancellation rates, providing overly positive growth expectations that could not be sustained.

Rosen Law Firm is notifying investors who purchased Medpace Holdings common stock between April 22, 2025 and February 9, 2026 about a securities class action lawsuit. The lawsuit alleges that Medpace made false and misleading statements regarding its backlog cancellation rates, claiming they were 'well behaved' while concealing material adverse facts. Investors must move the court by June 8, 2026 to serve as lead plaintiff.

A class action securities fraud lawsuit has been filed against Medpace Holdings for allegedly making materially false statements about its financial performance. The company missed its book-to-bill ratio guidance of 1.15, reporting only 1.04 due to record backlog cancellations. The stock fell 15.9% on February 10, 2026, following the disclosure. Investors who purchased shares between April 22, 2025 and February 9, 2026 can file a lead plaintiff motion by June 8, 2026.

Rosen Law Firm is soliciting investors who purchased Medpace Holdings common stock between April 22, 2025 and February 9, 2026 to join a securities class action lawsuit. The lawsuit alleges that Medpace made false and misleading statements regarding its backlog cancellation rates, which were described as 'well behaved' when they were actually problematic, leading to investors suffering damages when the true details became public.

Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies: Pinterest (PINS), New Era Energy & Digital (NUAI), Gossamer Bio (GOSS), and Medpace Holdings (MEDP). The lawsuits allege that defendants made false or misleading statements regarding business operations, financial performance, and prospects. Investors have until late May to early June 2026 to file lead plaintiff motions.

Levi & Korsinsky, LLP announces a securities fraud class action lawsuit against Medpace Holdings Inc. (NASDAQ: MEDP) for allegedly concealing backlog cancellation problems and misrepresenting book-to-bill ratios. Investors who purchased MEDP securities between April 22, 2025 and February 9, 2026 can seek lead plaintiff appointment by June 8, 2026. The stock declined over 15.9% ($84.30 per share) after the alleged misconduct surfaced.